

March 19, 1970

Dr. Allen P. Borger
Chas. Pfizer & Co.
Groton, Connecticut

Dear Allen,

As you will recall, Drs. Simeon and Nikolovski became interested in treating the failures of the doxepin-chlordiazepoxide study (as well as the doxepin successes after 8 weeks) with a "standard" drug. They selected thiothixene and the enclosed short protocol is the modification of the doxepin-chlordiazepoxide study that they used. Also, enclosed is the summary of their observations.

Separately I am sending you the case summaries, and copies of the various NIMH study forms - personal data inventory, drug study resume, brief psychiatric rating scale, clinical global impression and treatment emergent symptom scales. The Biometric Laboratory has analyzed this data and their report with a set of the data card outputs are enclosed.

The laboratory data was analyzed by Biodata, Inc. and their output is also enclosed.

Based on this information, we have proposed a more definitive study, a protocol of which has been sent to you.

I anticipate submitting the report of this pilot study to the *Journal of New Drugs* and I will notify you as soon as I have an answer.

Again, my thanks for your cooperation.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp